CINECA IRIS Institutional Research Information System

GAY, Francesca Maria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.952
EU - Europa 7.310
AS - Asia 4.633
SA - Sud America 480
OC - Oceania 206
AF - Africa 122
Continente sconosciuto - Info sul continente non disponibili 9
Totale 20.712
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.492
IT - Italia 2.442
CN - Cina 2.244
JP - Giappone 950
SE - Svezia 641
IE - Irlanda 580
DE - Germania 566
GB - Regno Unito 560
ES - Italia 452
FR - Francia 431
IN - India 302
CA - Canada 290
KR - Corea 217
VN - Vietnam 206
AT - Austria 200
UA - Ucraina 191
FI - Finlandia 185
PL - Polonia 180
AU - Australia 174
NL - Olanda 167
BR - Brasile 165
HK - Hong Kong 154
MX - Messico 139
CO - Colombia 134
SG - Singapore 131
TR - Turchia 126
RU - Federazione Russa 110
CH - Svizzera 108
BE - Belgio 104
TW - Taiwan 87
GR - Grecia 81
AR - Argentina 57
PT - Portogallo 57
TH - Thailandia 44
DK - Danimarca 43
HU - Ungheria 41
IL - Israele 35
CL - Cile 32
NZ - Nuova Zelanda 32
CZ - Repubblica Ceca 31
MA - Marocco 31
PE - Perù 26
NO - Norvegia 23
RS - Serbia 23
SN - Senegal 23
EC - Ecuador 22
HR - Croazia 22
BO - Bolivia 19
IR - Iran 19
EG - Egitto 18
RO - Romania 17
TN - Tunisia 17
DZ - Algeria 15
MY - Malesia 14
SA - Arabia Saudita 14
VE - Venezuela 14
BG - Bulgaria 12
ID - Indonesia 12
PH - Filippine 12
KZ - Kazakistan 11
UY - Uruguay 10
UZ - Uzbekistan 10
AE - Emirati Arabi Uniti 9
EU - Europa 9
PK - Pakistan 9
SI - Slovenia 9
ZA - Sudafrica 8
CR - Costa Rica 7
GT - Guatemala 7
SK - Slovacchia (Repubblica Slovacca) 7
NG - Nigeria 6
AM - Armenia 5
BY - Bielorussia 5
CU - Cuba 5
PA - Panama 5
BD - Bangladesh 4
JO - Giordania 4
MT - Malta 4
AL - Albania 3
BA - Bosnia-Erzegovina 3
EE - Estonia 3
LT - Lituania 3
LU - Lussemburgo 3
CY - Cipro 2
GE - Georgia 2
LK - Sri Lanka 2
MQ - Martinica 2
NI - Nicaragua 2
QA - Qatar 2
SV - El Salvador 2
AZ - Azerbaigian 1
BS - Bahamas 1
CD - Congo 1
GH - Ghana 1
IS - Islanda 1
KE - Kenya 1
LB - Libano 1
MD - Moldavia 1
MK - Macedonia 1
MN - Mongolia 1
Totale 20.707
Salva come PNG Salva come JPEG
Città #
Beijing 703
Chandler 611
Dublin 571
Fairfield 546
Ashburn 450
Houston 364
Florence 353
Redwood City 315
Woodbridge 284
Torino 283
Ann Arbor 281
Seattle 271
Wilmington 254
Tokyo 252
Cambridge 239
Nyköping 226
Princeton 188
Vienna 183
Shanghai 182
Medford 177
Dearborn 175
Turin 168
Villeurbanne 128
Milan 123
Duncan 121
Jacksonville 118
Madrid 116
Hangzhou 115
Ottawa 111
Dong Ket 110
London 107
Pisa 104
Warsaw 95
Guangzhou 85
New York 85
Barcelona 70
Rome 69
Nanjing 68
Central 65
Bogotá 63
Boston 61
Bologna 58
São Paulo 57
Taipei 53
Paris 51
Rochester 51
Toronto 51
Changsha 48
San Diego 48
Singapore 48
Chengdu 46
Sydney 46
San Mateo 45
Seoul 44
Boardman 42
Brussels 42
Fremont 42
Wuhan 41
Istanbul 38
Hebei 36
Mumbai 36
Padova 36
Norwalk 35
Osaka 35
Tianjin 35
Chicago 34
Helsinki 33
Moscow 33
Hong Kong 29
Zhengzhou 29
Los Angeles 28
Perth 28
Raritan 28
Athens 27
Chongqing 27
Manchester 27
Munich 27
Xian 27
Budapest 26
Frankfurt am Main 26
Washington 26
Amsterdam 25
Bari 25
Buenos Aires 25
Delhi 25
Nanchang 25
Atlanta 24
Berlin 24
Mexico City 24
Santiago 24
Zurich 24
Flushing 23
Melbourne 23
Catania 22
Lima 22
Phoenix 22
Central District 21
Dallas 21
Hanoi 21
Hyderabad 21
Totale 10.850
Salva come PNG Salva come JPEG
Nome #
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project 2.379
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: A randomised, multicentre, phase 3 trial 1.446
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial 1.329
MRD Assessment in Multiple Myeloma: Progress and Challenges 1.013
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN) 980
Plasma cell leukemia: update on biology and therapy 543
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma 464
Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors 432
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group 381
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension 368
Nuances in the Management of Older People With Multiple Myeloma 327
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma 318
The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents 293
Clinical and pharmacologic features of monoclonal antibodies and checkpoint blockade therapy in multiple myeloma 279
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications 260
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials 250
Novel investigational drugs active as single agents in multiple myeloma 238
From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives 218
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results 216
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients 204
Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma 193
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: Results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study 184
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma 180
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis 178
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis 170
Treatment of newly diagnosed elderly multiple myeloma 165
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: A pooled analysis 156
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when 143
Anti-CD38 monoclonal antibodies in multiple myeloma: another cook in the kitchen? 142
Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: A meta-analysis 140
Emerging drugs and combinations to treat multiple myeloma 139
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. 139
CD38 as an immunotherapeutic target in multiple myeloma 135
Special problems in the management of elderly patients with multiple myeloma 134
Therapeutic monoclonal antibodies and antibody products: Current practices and development in multiple myeloma 133
A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients 131
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial 129
ACHIEVEMENT OF COMPLETE REMISSION IS A STRONG PROGNOSTIC FACTOR IN 895 ELDERLY MYELOMA PATIENTS TREATED WITH MELPHALAN-PREDNISONE BASED-REGIMENS: RESULTS OF 3 MULTICENTER ITALIAN TRIALS 127
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma 118
Trichoderma species fungemia after high-dose chemotherapy and autologous stem cell transplantation: a case report 117
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma 116
Autologous Transplantation in Elderly Multiple Myeloma Patients: Is the Procedure Cost Effective? 114
EXPRESSION OF MET MRNA AS PROGNOSTIC MARKER IN MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL DRUGS 111
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA) 111
Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients 109
Promises and pitfalls in the use of PD-1/PD-L1 inhibitors in multiple myeloma 108
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing 108
Cardiovascular organ damage and blood pressure levels predict adverse events in multiple myeloma patients undergoing carfilzomib therapy 105
Redefining the treatment paradigm for multiple myeloma 104
Management of older patients with multiple myeloma 102
Lenalidomide maintenance with or without prednisone in newly diagnosed myeloma patients: A pooled analysis 101
Autologous transplant for myeloma: When the old meets the new 100
CyTOF®: A New Tool to Decipher the Immunomodulatory Activity of Daratumumab 100
Management of myeloma: an Italian perspective 98
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials 96
A Case-Matched Analysis Comparing Lenalidomide After Autologous or After Allogeneic Stem Cell Transplantation Demonstrates a Survival Advantage in Allografted Myeloma Patients 95
Time to First Progression, but Not B2-Microglobulin, Predicts Outcome in Myeloma Patients Who Received Thalidomide as Salvage Therapy. 94
The AKT/mTOR/P70S6K/4EB-P1 Signaling Pathway Is Activated in a Subset of Multiple Myeloma Patients and Correlates with High Serum Levels of Beta 2-Microglobulin. 94
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde 94
Daratumumab-Based Therapy for IgM Multiple Myeloma With Hyperviscosity Syndrome: A Case Report 91
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents 91
High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib. 90
Met Over-Expression Is a Prognostic Factor for Myeloma Patients Treated with Novel Agents 90
Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma 89
A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m2 (Mel200) Versus Melphalan 100 mg/m2 (Mel100) in Newly Diagnosed Myeloma Patients. 87
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network 86
Antibody-drug conjugates: when chemotherapy meets immuno-oncology 84
A Multicenter, Open Label Study of Oral Lenalidomide and Prednisone (RP) Followed by Oral Lenalidomide Melphalan and Prednisone (MPR) and Oral Lenalidomide Maintenance In Newly Diagnosed Elderly Multiple Myeloma Patients 83
VelcadeTM Plus Melphalan, Prednisone, and Thalidomide (V-MPT) for Advanced Multiple Myeloma. 83
Pursuing a curative approach in multiple myeloma: A review of new therapeutic strategies 79
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs 74
Treatment of newly diagnosed elderly multiple myeloma 73
Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients 73
Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network 71
A new combination for advanced multiple myeloma. 68
Maintenance Treatment and Survival in Patients With Myeloma A Systematic Review and Network Meta-analysis 68
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration 67
Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR 65
Multiple myeloma: management of adverse events 62
Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates 61
Safe Use of Carfilzomib in a Patient with Multiple Myeloma and Intermittent Type 1 Brugada ECG Pattern: A Case Report 61
Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate? 59
Can the dismal prognosis of patients with central nervous system plasma cell neoplasms be improved? 59
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study 58
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma 58
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 57
Moving Toward Continuous Therapy in Multiple Myeloma 57
Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma 56
Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma 55
The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens 55
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial 55
Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients 54
Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set 54
Thalidomide for treatment of multiple myeloma: 10 years later 53
Monoclonal antibodies currently in Phase II and III trials for multiple myeloma 53
Melphalan and its role in the management of patients with multiple myeloma 50
Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. 50
Multiple myeloma patients undergoing carfilzomib: Development and validation of a risk score for cardiovascular adverse events prediction 50
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials 49
Chromosome 1 abnormalities in newly diagnosed elderly multiple myeloma patients treated with novel therapies. 48
Totale 19.577
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.731
article - articoli 0
book - libri 0
conference - conferenze 3.021
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.752
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019493 0 0 0 0 0 0 0 0 0 107 257 129
2019/20202.123 75 60 88 259 144 242 196 163 349 224 193 130
2020/20213.494 152 170 236 231 309 325 311 321 302 322 347 468
2021/20223.427 214 223 222 343 220 199 271 201 157 260 449 668
2022/20235.032 288 295 233 429 399 779 443 434 501 302 457 472
2023/20244.102 470 545 394 478 414 463 423 429 138 348 0 0
Totale 21.336